1/91
Looks like no tags are added yet.
2nd
Prostate cancer is the _______ most common malignancy of males in the US.
increases
Risk of prostate cancer __________ with age
66
What is the avg age of dx of prostate cancer?
black
There is an increased incidence of prostate cancer with ______ males
1 out of 8
__________ get dx with prostate cancer in their lifetime
prostate gland
heart shaped under bladder
BPH
is not a precursor for prostate cancer
5- alpha reducatase
Testosterone -> ____________ -> DHT
peripheral zone
most easily palpated and cells for prostate cancer mature here 1st
DHT
androgenic receptors are more sensitive to ________
LHRH
hypothalamus releases _________ that goes to the Pituitary.
LH and FSH
The pituitary releases ________ to the testes.
testosterone
The testes release _________ (95%) that is convered to DHT.
1) predisposing risk factors
2) cellular transformation
3) tumor development and progession
What are the pathways to prostate cancer?
predisposing risk factors for prostate cancer
-hereditary genetics: inherited mutations (BRCA1/2, HOXB13)
-age and epigenetics (accumulation of random DNA errors over time)
-environment and lifestyle (smoking, high fat diet, inflammation, obesity, hormonal imbalance)
cellular transformation pathway to prostate cancer
-oncogenes activated that increase cell multiplication
-fix damage or kill damaged cells
-self sufficiency in growth signals (AR driven)
-insensitivity to anti-growth signals
-tissue invasion and metastasis
-evading apoptosis
What are the hallmarks of prostate cancer?
digital rectal exam (DRE) and prostate specific antigen (PSA)
What are the screening for prostate cancer?
PSA
-useful for early detection
-useful for monitoring androgen-deprivation therapy or chemotherapy
earlier
Patients with increased risk may begin screens _________
< 4
Normal PSA:
> 10
Cancer PSA:
declining
There is a _________ rate of death with prostate cancer.
90%
What % of prostate cancer has early dx?
NIH-sponsored Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial
landmark trial
55-74 yo no evidence of mortality benefit in annual screenings for prostate cancer
age 50 is rec for avg screening (every 2-4 yrs)
STOP screening at 70
Preventative Services Task Force (USPSTF) recommendations for prostate cancer screening:
≥ 10 yrs
Pts who are getting screened for prostate cancer should have a life expectancy of _________
urology
abnormal PSA should be referred to ___________
stage 1 prostate cancer
-T1-2a
-N0
-M0
-tumor is small and cannot be detected through digital rectal examination (DRE)
stage 2
-T2b-c
-N0
-M0
-the cancerous tissue is larger, but still be confined within the prostate
stage 3
-T3
-N0
-M0
-the cancer has invaded surrounding tissues
Stage 4
-T4
-N1
-M1
-the cancer has spread to lymph nodes, bones, or other distant parts of the body beyond the pelvic region
< 10
PSA level in stage 1:
10-19.9
PSA level in stage 2a:
≥ 20
PSA level in stage 2b:
any
PSA level in stage 3 and 4:
gleason score
-Grading scale for prostate cancer cells
-Ranges 2-10
-Indicative of how likely a tumor is to spread
low/very low
gleason score ≤ 6
intermediate (favorable/unfavorable)
Gleason Score 7 (3+4)
Gleason Score 7 (4+3)
high/very high
Gleason Score 8
Gleason Score 9-10
2
There are ____ gleason score samples taken in a biopsy.
well differentiated
gleason's pattern scale 1
3+ gleasons pattern scale
poorly differentiated anaplastic
1) observation
2) radiation
3) radical prostatectomy
Tx for TNM stage T1 or T2a; Gleason ≤ 6; PSA < 10
1) observation
2) Radical prostatectomy w/ pelvic lymph node dissection
3) Radiation therapy +/- ADT +/- brachytherapy
Tx for TNM stage T2b-T2c; Gleason 7; PSA 10-20:
1) Radiation therapy + ADT +/- brachytherapy
2) Radical prostatectomy w/ pelvic lymph node dissection
Tx for TNM stage T3a; Gleason 8-10; PSA > 20:
1) Radiation therapy + ADT +/- brachytherapy
2) Radical prostatectomy w/ pelvic lymph node dissection
3) ADT
Tx for TNM stage T3b-T4; gleason > 4 scores of 8-10:
-watchful waiting
-surgery
-radiation
What are the non-med tx options for prostate cancer?
Watchful Waiting
for asymptomatic patients or patients who cannot tolerate treatment
surgery
-prostatectomy
-possible pelvic lymph node dissection
-bilateral orchiectomy (removal of testes)
radiation
2 general types
-External beam radiotherapy
-Brachytherapy: implantation of radioactive beads
LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS
-affective for prostate cancer
-neg feedback control tells pituitary to stop releasing LH/FSH (bottoms out)
-1st 2 weeks more s/s due to DHT surge but after it bottoms out due to neg feedback loop
Currently available LH-RA:
-Lupron (leuprolide) daily
-Lupron Depot (leuprolide depot) 1-6 months
-Viadur (leuprolide intradermal implant) 12 months
-Trelstar Depot (triptorelin depot) 4 weeks
-Trelstar LA (triptorelin) 12 weeks
-Zoladex (goserelin subcutaneous implant) 28 days
-Disease flare-up during first week of therapy caused by initial induction of LH and FSH
-Hot flashes
-Impotence
-Decreased libido
-Injection site reactions
LH-RA AEs:
80%
LH-RH agonists have response rates as high as _______
GONADOTROPIN-RELEASING HORMONE ANTAGONISTS
-bind to GnRH receptors and antagonize pituitary
-no flare up
-castrate levels of testosterone in 1 week
GnRH antagoinsts
-Used as an alternative to LH-RH agonists
-Similar MOA in that it reduces testosterone production to castrate levels
Lupron
Leuprolide
Lupron Depot
leuprolide depot
Viadur
leuprolide intradermal implant)
Trelstar Depot
triptorelin depot)
Trelstar LA
triptorelin
Zoladex
goserelin subcutaneous implant
Firmagon
degrelix for injection
Orgovyx
relugolix tabs
-Hot flashes
-Fatigue, tiredness
-Muscle/joint pain
-Decreased libido
-Injection site reactions
-QT prolongation
-Bone mineral density loss
Degarelix AEs:
-Hot flashes
-Fatigue, tiredness
-Muscle/joint pain
-Decreased libido
-Hyperglycemia
-Hypertriglyceridemia
-CYP 3A4 substrate
-QT prolongation
-Bone mineral density loss
Relugolix AEs:
ANTIANDROGENS
block androgen receptors from binding androgens
1st Generation Antiandrogens
-Eulexin (flutamide) 750mg/day
-Casodex (bicalutamide) 50mg/day
-Nilandron (nilutamide) 300mg/day 1st month; 150mg/day thereafter
2nd generation Antiandrogens
-Erleada (apalutamide)
-Xtandi (enzalutamide)
-Nubeqa (darolutamide)
Eulexin
flutamide
Casodex
bicalutamide
Nilandron
nilutamide
Erleada
apalutamide
Xtandi
enzalutamide
Nubeqa
darolutamide
abiraterone acetate
inhibits synthesis
Erleada
apalutamide
casodex (bicalutamide)
-Only 1st gen antiandrogen still available
-good med to start prior to LH-RH agonist (flare up)
full
2nd gen antiandrogens are _____ antagonists (very effective)
Erleada
Apalutamide
Apalutamide (Erleada)
-240 mg orally daily
-AE: hypothyroidism, rash, falls, fractures
Enzalutamide (Xtandi)
-160 mg orally daily
-AE: serizures/mental impairment, CV events, fatigue, falls
Darolutamide (Nubeqa)
-600 mg orally twice daily with food
-AE: fatigue
no (CYP interaction)
Can you use Relngolix with antiandrogens?
NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (NMCRPC)
- Patients receive ADT x prolonged period
- Biochemical progression during this time despite serum testosterone concentration < 50 ng/dL and no s/sx metastasis
-≥ 25% increase PSA concentration; 3 weeks later- increased PSA is confirmed
-PSA doubling time ≤ 10 months: 2nd gen antiandrogens + ADT
over-dx and over-tx
What can widespread screening for prostate cancer lead to?
leads to urinary incontinence and ED (20-70%)
What is a possible complication of radical prostatectomy and radiation therapy?
-fever, pain, hematuria
-pos urine cultures, hematospermia
What are the complications from biopsy?
-5 alpha reductase inhibitors?
-Finasteride (Proscar)
-Dutasteride (Avodart)
NON FDA APPROVED FOR PREVENTION
What can be used as preventative for prostate cancer?
Proscar
Finasteride
Avodart
Dutasteride